What is SLU-PP-332?
Here is the whole picture in one card, before the detail.
| Question | Answer |
|---|---|
| Molecule type | Small synthetic molecule, not a peptide |
| Target | Estrogen-related receptors ERR alpha, beta and gamma, strongest at ERR alpha |
| Highest level of evidence | Mouse studies |
| Human trials | None found, October 2026 |
| Approved medicine | None found |
| WADA list | Named in the 2027 list, class S4, in force 1 January 2027 |
| Glow Labs stock | 5mg vial, sold out, pre-order |
The name is a lab code. The teams behind the first papers worked in St. Louis, Missouri, including chemists at Saint Louis University. The papers do not spell out the letters, so we do not guess.
Glow Labs lists SLU-PP-332 for laboratory research only. It can be pre-ordered on WhatsApp.
Sources: PubChem, Slu-PP-332, CID 5338394, National Library of Medicine. Billon C et al, Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity, ACS Chem Biol, 2023. Moller T et al, Rapid Commun Mass Spectrom, 2026. PubMed search "SLU-PP-332 AND clinical trial[pt]" (0 records) and ClinicalTrials.gov search for SLU-PP-332 (0 studies), both run 25 October 2026. World Anti-Doping Agency, Prohibited List, S4.4 metabolic modulators, read 26 October 2026. World Anti-Doping Agency, 2027 Prohibited List, S4.4.1 metabolic modulators, in force 1 January 2027, read 26 October 2026.
Questions about this guide?
Ask on WhatsAppNot a peptide
Peptides are built from amino acids linked one after another. SLU-PP-332 contains none. It is a compact ring-based organic molecule with just 36 atoms. Comparing it with a real peptide makes the gap clear.
| SLU-PP-332 | MOTS-c | |
|---|---|---|
| Type | Small molecule | Peptide |
| Built from | Carbon rings with nitrogen and oxygen groups | 16 amino acids |
| Formula | C18H14N2O2 | C101H152N28O22S2 |
| Molecular weight | 290.3 g/mol | 2174.6 g/mol |
| PubChem record | CID 5338394 | CID 146675088 |
MOTS-c is about seven and a half times heavier. Our guide to what counts as a peptide explains the definition in more depth.
Sources: PubChem, Slu-PP-332, CID 5338394, National Library of Medicine. PubChem, Mots-c, CID 146675088, National Library of Medicine.
What ERRs are
ERR stands for estrogen-related receptor. There are three types: alpha, beta and gamma. Despite the name, they are not oestrogen receptors and do not respond to oestrogen. They got the name because their gene sequence looks similar.
ERRs are called orphan nuclear receptors. "Nuclear" means they work inside the cell nucleus, switching genes on and off. "Orphan" means scientists have not found a natural molecule in the body that binds them. The 2026 SLU-PP-915 paper describes ERRs as controlling genes for mitochondria, fat breakdown and the Krebs pathway. That is why a compound that switches them on draws interest in energy research.
Sources: Billon C et al, Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity, ACS Chem Biol, 2023. Billon C et al, An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity, J Pharmacol Exp Ther, 2026.
What was studied
Mouse exercise studies
The 2023 ACS Chem Biol paper described SLU-PP-332 as a pan-ERR agonist, meaning it activates all three types. In muscle cells it raised mitochondrial activity. In mice, the team counted muscle fibre types and measured running endurance. They also found it switched on a set of genes that exercise normally turns on. This is where the label "exercise mimetic" comes from. It is a description of a mouse finding.
A 2024 paper tested it in two mouse models of metabolic syndrome. The team measured energy use, fat breakdown by cells, fat mass and insulin response in those mice.
Heart failure models
A 2024 Circulation paper tested SLU-PP-332 and a second compound, SLU-PP-915, in mice with heart failure caused by pressure overload. The team measured heart pumping, scarring and survival, plus thousands of gene and metabolite changes.
Newer analogues
The field is moving fast. A 2026 paper reported that SLU-PP-332 does not get into the body well when given by mouth to mice, and described SLU-PP-915, a different molecule that does. Another 2026 paper mapped which parts of the SLU-PP-332 structure matter most and made new versions of it. Both are signs of early-stage drug chemistry, not of a finished product.
Sources: Billon C et al, Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity, ACS Chem Biol, 2023. Billon C et al, A synthetic ERR agonist alleviates metabolic syndrome, J Pharmacol Exp Ther, 2024. Xu W et al, Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function, Circulation, 2024. Okda HE et al, Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling, Int J Biol Macromol, 2026. Billon C et al, An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity, J Pharmacol Exp Ther, 2026.
What is not known
On 25 October 2026 we searched PubMed for clinical trial records on SLU-PP-332 and found none. ClinicalTrials.gov also listed no registered studies. Without a human study, how it behaves in people is an open question.
Every finding above is from cells or mice. Mouse findings often fail to carry over to humans. Long-term safety has not been studied in any species that we could find.
Sport and the law
The World Anti-Doping Agency list in force during 2026 does not name SLU-PP-332. WADA's 2027 Prohibited List, in force from 1 January 2027, names SLU-PP-332 as an example of a banned metabolic modulator (class S4), along with SLU-PP-915. In 2026 anti-doping chemists published methods to detect SLU-PP-332, SLU-PP-915 and their breakdown products, and described both as compounds with doping potential.
No TGA page naming SLU-PP-332 was found for this guide, so we make no claim about its Australian status. It is offered strictly as a lab chemical.
Sources: Moller T et al, Rapid Commun Mass Spectrom, 2026. World Anti-Doping Agency, Prohibited List, S4.4 metabolic modulators, read 26 October 2026. World Anti-Doping Agency, 2027 Prohibited List, S4.4.1 metabolic modulators, in force 1 January 2027, read 26 October 2026.
Storing SLU-PP-332
SLU-PP-332 comes as a dry solid in a vial. Keep the container sealed, cool, dry and dark to limit slow chemical change. Our guide on how to store peptides covers general vial handling. 5-Amino-1MQ is the other small molecule in our catalogue.
FAQ
What is SLU-PP-332?
A small lab-made molecule that switches on the estrogen-related receptors. It is not a peptide.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 has no amino acids at all, so chemists class it as a small molecule. The phrase "SLU-PP-332 peptide" is common in search but chemically wrong.
What is an ERR agonist?
An agonist switches a receptor on. An ERR agonist switches on estrogen-related receptors, which control genes linked to energy use in cells.
Has SLU-PP-332 been tested in people?
Not that we could find. Our October 2026 searches of PubMed and ClinicalTrials.gov returned no human trials.
Is SLU-PP-332 on the WADA list?
Yes, from 2027. The 2027 list, in force from 1 January 2027, names it under S4 metabolic modulators. Anti-doping scientists have also published ways to detect it.
Is SLU-PP-332 active when given by mouth?
A 2026 mouse paper said it lacks oral bioavailability, and described SLU-PP-915 as an orally active ERR agonist.
How is SLU-PP-332 stored?
In a sealed vial, kept cool, dry and away from light until it is used in the lab.
Sources: PubChem, Slu-PP-332, CID 5338394, National Library of Medicine. Billon C et al, Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity, ACS Chem Biol, 2023. Billon C et al, An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity, J Pharmacol Exp Ther, 2026. Moller T et al, Rapid Commun Mass Spectrom, 2026. PubMed search "SLU-PP-332 AND clinical trial[pt]" (0 records) and ClinicalTrials.gov search for SLU-PP-332 (0 studies), both run 25 October 2026. World Anti-Doping Agency, 2027 Prohibited List, S4.4.1 metabolic modulators, in force 1 January 2027, read 26 October 2026.
Sources
- PubChem, Slu-PP-332, CID 5338394, National Library of Medicine.
- Billon C et al, Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity, ACS Chem Biol, 2023.
- Billon C et al, A synthetic ERR agonist alleviates metabolic syndrome, J Pharmacol Exp Ther, 2024.
- Xu W et al, Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function, Circulation, 2024.
- Okda HE et al, Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling, Int J Biol Macromol, 2026.
- Billon C et al, An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity, J Pharmacol Exp Ther, 2026.
- Moller T et al, In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915: novel pan-ERR agonists with doping potential, Rapid Commun Mass Spectrom, 2026.
- PubMed search "SLU-PP-332 AND clinical trial[pt]" (0 records) and ClinicalTrials.gov search for SLU-PP-332 (0 studies), both run 25 October 2026.
- World Anti-Doping Agency, Prohibited List, S4.4 metabolic modulators, read 26 October 2026.
- PubChem, Mots-c, CID 146675088, National Library of Medicine.
- World Anti-Doping Agency, 2027 Prohibited List, S4.4.1 metabolic modulators, in force 1 January 2027, read 26 October 2026.
